Financials

News Ideas Discussions Technicals Forecast Seasonals

X2S fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to SINOPHARM GRP CO. H YC 1 operating, investing, and financing activities

X2S free cash flow for H2 24 is 5.09 B EUR. For 2024, X2S free cash flow was -730.03 M EUR and operating cash flow was -500.77 M EUR.

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: EUR

TTM

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—